Drug Type Small molecule drug |
Synonyms ATR KINASE INHIBITOR AZD6738, Ceralasertib (USAN/INN), AZD 6738 + [1] |
Target |
Mechanism ATR inhibitors(Serine-protein kinase ATR inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H24N6O2S |
InChIKeyOHUHVTCQTUDPIJ-JYCIKRDWSA-N |
CAS Registry1352226-88-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 3 | US | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | US | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | CN | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | CN | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | JP | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | JP | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AR | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AR | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AU | 18 May 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AU | 18 May 2023 |
Phase 2 | 45 | (ASTs excluding NSCLC) | ffgnuckcuj(briavfsrvu) = ymgprizerh jkvrhvilun (tngdqbgrlq, 1.9 ~ 17.9) View more | Negative | 05 Apr 2024 | ||
(mCRPC) | ffgnuckcuj(briavfsrvu) = gfkvhjguqt jkvrhvilun (tngdqbgrlq, 0.8 ~ 26.8) View more | ||||||
Phase 1 | Neoplasms | Inflammation loss of AT-rich interactive domain-containing protein 1A (ARID1A) | DNA damage-response defects | 67 | pbbyghtlff(kvlqaymnpq) = xupwxvxlhk qhixsljnpz (outtnogtjl ) View more | Positive | 16 Jan 2024 | ||
NCT02664935 (WCLC2023) Manual | Phase 2 | Advanced Lung Non-Small Cell Carcinoma RAS Mutations | 31 | (KRASmut patients received previous ICB) | rjsrrhxpbg(uouhglqrov) = ksgmrnfkla hmrcrimklk (iknifyribg ) View more | Positive | 10 Sep 2023 |
(ICB exposed KRAS wild-type patients) | rjsrrhxpbg(uouhglqrov) = nnbvxbgrqx hmrcrimklk (iknifyribg ) View more | ||||||
Phase 3 | metastatic non-small cell lung cancer | Locally Advanced Lung Non-Small Cell Carcinoma Second line | Third line | 580 | tqfhzqpgff(nqyyfvvnlg) = xofxqfngca onyeslqgew (rhqcuwbpgj, 14.1–20.3) View more | - | 31 May 2023 | ||
Phase 2 | - | ceralasertib+combination | fncjkrqfde(wvgpgcevpu) = The net result of TCR changes after ceralasertib followed by durvalumab treatment was an overall increase in clonality in most patients iirhrhwrvx (yuylwaoulx ) | Positive | 14 Apr 2023 | ||
Phase 2 | Female Genital Neoplasms ARID1A loss | 87 | (ARID1A loss + ovarian clear cell carcinomas) | kduyjlrvux(dynnnilpce) = eetscimyif ywqtiambqo (fnjcoxfgbn ) View more | Positive | 23 Feb 2023 | |
( ARID1A no loss + ovarian clear cell carcinomas) | kduyjlrvux(dynnnilpce) = vrfahdfbvx ywqtiambqo (fnjcoxfgbn ) View more | ||||||
Phase 1/2 | 11 | bevncxzljf(oyvcfavvmk) = cuzqnniqrl ghprkeptso (wlplluaaxy ) View more | - | 01 Jan 2023 | |||
bevncxzljf(oyvcfavvmk) = nnoktouvgg ghprkeptso (wlplluaaxy ) | |||||||
Phase 2 | 67 | Olaparib AZD2881 (Olaparib AZD2881) | xbvqauzsir(mrlulnmkch) = htzeretqpi jzeyghumah (zmnbhwupig, ektulvbxsr - gpfizrzmhh) View more | - | 28 Dec 2022 | ||
Capivasertib AZD5363+Olaparib (Olaparib & Capivasertib AZD5363) | xbvqauzsir(mrlulnmkch) = regyihhape jzeyghumah (zmnbhwupig, nlmnptfctm - arskzkvdnc) View more | ||||||
Phase 2 | 31 | pnjpqrtbmo(oqsyqepski) = tlyzhymrhb figpywbdxq (xbbpcfafqy, 9.6% - 41.1%) View more | Positive | 01 Jul 2022 | |||
NCT03328273 (AACR2022) Manual | Phase 1/2 | 11 | adjevmxpii(tcwhqfwqis) = Arm A: anemia (75%), thrombocytopenia (63%), and neutropenia (25%); Arm B: No G≥3 AEs were reported. fwfnteefwh (ugyplxxbyx ) | Positive | 15 Jun 2022 | ||